|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
METHODS |
From Hoffman-La Roche Inc, Nutley, New Jersey (Dr Zhang); Hoffman-La Roche AG, Basel, Switzerland (Ms Silkey); and Roche Palo Alto LLC, Palo Alto, California (Ms Schumacher, Ms Wang, Ms Raval, and Dr Caulfield).
This study compares 4 baseline correction methods on the effect of moxifloxacin on the QT/QTc interval: (1) day –1 time-matched baseline electrocardiograms (ECGs), (2) 3 triplicate predose ECGs, (3) 1 triplicate predose ECG, and (4) no baseline correction. Forty-four healthy subjects receive a single dose of moxifloxacin (400 mg), placebo, and 2 doses of an investigational agent in a 4-period crossover fashion. For all 4 methods, the largest mean difference from placebo in the moxifloxacin study-specific QTc is 11.97 to 13.23 ms and occurs at 3 to 4 hours postdose; the lower 90% confidence interval is greater than 5 ms from 2 to 8 hours. The average standard error of the mean is 1.36 ms for 3 triplicate predose ECGs, 1.40 ms for 1 triplicate predose ECG, 1.60 ms for day –1 time-matched baseline ECGs, and 1.65 ms for no baseline correction. Predose baseline methods (3 or 1 triplicate ECGs) are superior to the day –1 time-matched baseline correction or without baseline correction.
Key Words: Baseline-Adjusted thorough QT/QTc study (TQT study) moxifloxacin time-matched baseline predose baseline
Address for reprints: Xiaoping Zhang, PhD, Department of Clinical Pharmacology, Hoffman-La Roche Inc, 340 Kingsland Street, Nutley, NJ 07110; e-mail: Amy.zhang{at}roche.com.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |